loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Seclidemstat, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Seclidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: 1423715-37-0, Sp-2577, Sp2577, Tyh386v3wj, N-[(e)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide, Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
    Molecular Formula
    C20H23ClN4O4S
    Molecular Weight
    450.9  g/mol
    InChI Key
    MVSQDUZRRVBYLA-HYARGMPZSA-N
    FDA UNII
    TYH386V3WJ
    Seclidemstat is an orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
    2.1.2 InChI
    InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+
    2.1.3 InChI Key
    MVSQDUZRRVBYLA-HYARGMPZSA-N
    2.1.4 Canonical SMILES
    CC(=NNC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)C3=C(C=CC(=C3)Cl)O
    2.1.5 Isomeric SMILES
    C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O
    2.2 Other Identifiers
    2.2.1 UNII
    TYH386V3WJ
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1423715-37-0

    2. Sp-2577

    3. Sp2577

    4. Tyh386v3wj

    5. N-[(e)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide

    6. Benzoic Acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide

    7. Seclidemstat [inn]

    8. Unii-tyh386v3wj

    9. Seclidemstat [who-dd]

    10. Chembl4297641

    11. Schembl14697017

    12. Schembl14697019

    13. (e)-n'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-((4-methylpiperazin-1-yl)sulfonyl)benzohydrazide

    14. Ex-a3574

    15. Ygc71537

    16. Nsc833973

    17. S6722

    18. Akos037648727

    19. Nsc-833973

    20. Bs-15371

    21. Hy-103713

    22. Cs-0039281

    2.4 Create Date
    2019-01-15
    3 Chemical and Physical Properties
    Molecular Weight 450.9 g/mol
    Molecular Formula C20H23ClN4O4S
    XLogP32.3
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count5
    Exact Mass450.1128541 g/mol
    Monoisotopic Mass450.1128541 g/mol
    Topological Polar Surface Area111 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity734
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    Post Enquiry
    POST ENQUIRY